Overview of Vasculera

Property	Description
Active Ingredient	Diosmiplex (Purified Diosmin)
Form	Oral Tablet
Pharmacological Class	Phlebotonic Agent / Venoactive Drug
General Purpose	Dietary management of Chronic Venous Insufficiency (CVI) symptoms
Origin	Derived from natural bioflavonoids

What is Vasculera and What Type of Product is It?

Vasculera is a distinct oral formulation classified as a Medical Food, intended specifically for the clinical dietary management of the metabolic deficiencies associated with Chronic Venous Insufficiency (CVI). This classification sets it apart from conventional prescription drugs and standard dietary supplements, affirming its role in managing a condition for which scientific evidence supports distinctive nutritional requirements. The product is dispensed as a tablet and is positioned for adults who require targeted, specialized micronutrient support for their venous integrity.

Composition: Understanding Diosmiplex and Its Pharmacological Class

The active entity in Vasculera is Diosmiplex (INN: Diosmin), a proprietary, high-density micronized flavonoid blend derived semi-synthetically from natural citrus bioflavonoids. This compound is categorized as a phlebotonic agent or venoactive drug due to its specific activity on the vascular system. Its unique differentiating factor lies in its composition: it is formulated as a high-density blend that undergoes an advanced micronization process. This technical refinement of the purified diosmin is intended to enhance potential systemic absorption and bioavailability compared to generic, non-micronized bioflavonoid preparations.

General Purpose and Role as a Vascular Protectant

The general purpose of Vasculera is to function as a vascular protectant, offering support to both the microcirculation and macrocirculation. Clinically recognized for this role, its mechanism focuses on improving venous tone and reducing the excessive leakiness, or capillary hyperpermeability, of the smallest blood vessels. This action assists in mitigating the chronic symptoms of venous dysfunction, such as the persistent feeling of heaviness and discomfort, and helps to decrease the associated fluid accumulation (venous edema) often experienced in the lower limbs.

What side effects are possible with Vasculera?

Possible Side Effects and Safety Information

The official safety profile for Vasculera, a Medical Food containing Diosmiplex, is structured by classifying documented adverse reactions according to frequency and the body system affected, consistent with regulatory standards.

Frequency-Classified Adverse Reactions

The majority of documented effects are related to the Gastrointestinal and Nervous System domains, as classified in official regulatory documents.

Classification	Examples of Documented Effects
Common	Upset stomach, Headache, Diarrhea, Nausea, Vomiting, Dyspepsia
Uncommon	Colitis
Rare	Dizziness, Rash, Pruritus, Urticaria
Frequency Not Known	Abdominal pain, Quincke's Edema (Angioedema)

Serious Adverse Reactions and Safety Restrictions

Regulatory labeling identifies specific signs requiring attention, including indicators of a severe allergic reaction (such as swelling of the face, lips, or throat) and signs potentially indicative of a blood clot (such as pain or swelling in one leg).

The product is contraindicated in individuals with a known hypersensitivity or allergy to Diosmiplex or any of its non-active components, such as povidone, cellulose, or corn products. Official safety notes also advise against use during pregnancy and lactation, with the decision for use in these populations deferred to the patient's physician. Furthermore, regulatory documents note potential high-level interactions that may alter the safety profile when used with certain medications, including Chlorzoxazone, Diclofenac, and Metronidazole.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Vasculera's active component, Diosmiplex, is centered on the absence of documented toxicity following high-dose exposure. Clinical data shows that even acute intake exceeding the standard amount, such as 5000 mg per day for four days, did not produce toxic effects in human studies.

Overdose Scope	Regulatory Documentation Findings
Documented overdose presentations:	No reported cases of overdose are documented in clinical or post-marketing data for this product.
Physiological systems affected:	Predicted clinical manifestations primarily involve the Gastrointestinal system, which may include symptoms such as nausea, vomiting, dyspepsia, and diarrhea.
Emergency-response statements:	Seek emergency medical attention immediately in the event of a suspected overdose.
Required help-seeking action:	Contact a Poison Help Center immediately (e.g., the 1-800-222-1222 line in the U.S.).

Overdose Management and Regulatory Context

The regulatory context for overdose emphasizes mandated emergency contact rather than specific intervention protocols. The management approach described in official documents is broadly symptomatic and supportive, which is consistent with the product's low toxicity profile. There is no specific antidote documented in the regulatory prescribing information, and no specific population-based considerations (e.g., for renal or hepatic impairment) are detailed in official sources regarding overdose.

Therapeutic Uses of Vasculera

Quick Facts

May assist in the clinical dietary management of chronic venous disease (CVD).
May help manage manifestations of CVD such as varicose veins, spider veins, and leg edema.
Used under physician supervision for the dietary management of the metabolic processes of CVD.
May provide support for symptoms including leg heaviness, aching, and discomfort.

What Vasculera Treats: Main Uses and Benefits

Vasculera is a prescription medical food product intended for the clinical dietary management of the metabolic processes associated with chronic venous disease (CVD). This condition involves issues with blood circulation in the veins, particularly in the legs.

For patients with CVD, this product may help manage various related manifestations and associated symptoms. These may include addressing the discomfort and signs of conditions like varicose veins, spider veins, edema (leg swelling), and venous ulcers. It is also indicated for the management of the symptoms of hemorrhoids.

The primary ingredient has demonstrated a capacity to support venous health and assist in the management of symptoms such as a feeling of leg heaviness, aching, cramping, and pain that may be worse when standing. The usage of this product must be supervised by a physician as part of a comprehensive management plan for the condition.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vasculera? — Official Regulatory Information

The eligibility profile for Vasculera, a prescription medical food, is defined by regulatory documents that establish specific patient populations for whom the product is allowed, contraindicated, or restricted.

Absolute Contraindication

Vasculera is strictly contraindicated for individuals with a known hypersensitivity or allergy to any component of the product, including diosmiplex, cellulose, povidone, or corn products. Use is prohibited in this group.

Age and Conditional Use

The product is indicated for use in adults. However, use in pediatric patients is not established, as the product has not been tested in children. For pregnant and nursing women, the product has not been fully tested. Consequently, the decision to use Vasculera in these populations is classified as conditional and rests solely at the discretion of the prescriber.

Organ Function and Comorbidities

Official labeling does not impose formal restrictions related to organ function. Clinical data indicates no clinically significant changes were observed in hepatic or renal function during studies, suggesting the absence of formal limitations based on liver or kidney impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines the interaction profile of Vasculera (Diosmiplex) through its potential to alter the circulating levels of co-administered medicines, a mechanism classified as a pharmacokinetic interaction.

Documented Pharmacokinetic Interaction Patterns

Interaction Type	Official Regulatory Statement
Metabolic Enzyme Inhibition	The active ingredient, diosmin, is documented as an inhibitor of Cytochrome P450 (CYP) 2C9 in vitro.
Transporter Inhibition	Diosmin is also documented as an inhibitor of the P-glycoprotein (P-gp) efflux transporter in vitro.

Interaction Outcomes and Restrictions

The documented inhibition of CYP2C9 and P-gp may result in an increase in the plasma concentrations and systemic exposure of other co-administered medicinal products that are substrates for these pathways. Due to this exposure-modifying effect, official labeling directs specific attention toward co-administration with narrow therapeutic index drugs.

Substances specifically noted in regulatory text as requiring caution include CYP2C9 substrates, such as Warfarin, and P-gp substrates, such as Digoxin or Dabigatran. While no combinations are formally classified as contraindicated, the regulatory constraint advises that co-administration may require monitoring for altered plasma concentrations of the co-administered drug. No mandatory administration-timing rules or interactions with food, alcohol, or herbal products are explicitly specified in the official prescribing information.

Mechanism of Action

Venous Tone Potentiation via Enzyme Inhibition

The primary venotonic action is initiated by the active metabolite, Diosmetin, which engages the noradrenergic signaling pathway. It achieves this by inhibiting the enzyme Catechol-O-methyltransferase (COMT). This enzymatic inhibition reduces the breakdown of the natural vasoconstrictor, Norepinephrine (NE), thereby increasing its effective concentration at the venous smooth muscle cells. This action potentiates the venous tone, increasing the resistance to distension.

Microvascular Integrity Management and Anti-inflammatory Modulation

The drug manages the microcirculation and modulates the inflammatory cascade and endothelial health. Diosmetin limits the adhesion and activation of leukocytes to the capillary lining, a critical step in microvascular disruption. It also acts as an anti-inflammatory modulator by inhibiting the 5-lipoxygenase (5-LOX) enzyme, restricting the production of pro-inflammatory mediators. This dual action on cell and enzyme systems reduces capillary hyperpermeability and limits transcapillary fluid filtration.

Synergistic Buffering of the Local Tissue Environment

The secondary component, Alka4-complex, influences the local tissue environment by acting as a systemic buffering agent. This addresses the local metabolic acidosis frequently present in venous tissues; acidosis is known to alter smooth muscle and endothelial cell function. This physicochemical mechanism supports the Diosmetin-mediated actions, facilitating the noradrenergic response and anti-inflammatory effects within the localized microenvironment.

Dosage and Administration Information

How to Use Vasculera: Official Administration Guidelines

Vasculera is an oral tablet formulated as a prescription medical food, and its administration must occur under the supervision of a physician. The appropriate dosing regimen and duration of use are determined by the condition being managed, following specific guidelines outlined in the official prescribing information.

Dosing and Frequency

Clinical Context	Recommended Dosing Regimen	Duration Pattern
Chronic Venous Disease (CVD)	One 630 mg tablet once daily.	Intended for sustained, daily maintenance intake.
Hemorrhoidal Flare (Initial)	One 630 mg tablet three times daily for four days.	Acute, short-term course (13 days total).
Hemorrhoidal Flare (Transition)	One 630 mg tablet twice daily for nine days.	Follows the initial higher-dose phase.
Chronic Hemorrhoid Maintenance	One 630 mg tablet once daily.	Resumes daily maintenance after acute flare resolution.

Administration Instructions

Instruction	Detail
Route and Form	The product is taken orally as an intact tablet.
Timing with Meals	The tablet can be consumed with or without food. Taking the tablet with food is specifically recommended if indigestion occurs.
Missed Dose	If a dose is missed, the patient should resume the normal dosing schedule. Do not take two doses at one time to make up for the dose that was missed.
Use in Special Populations	Use in pregnant or nursing women is solely at the discretion of the prescribing physician, as full safety data is not available for these groups.

Recent Clinical Evidence

Research evidence / Overview of studies for Vasculera

Evidence for Use in Chronic Venous Disease (CVD) and CVI

Research for the main ingredient in Vasculera, Purified Diosmin, was studied for conditions related to Chronic Venous Disease (CVD) and Chronic Venous Insufficiency (CVI) across many international settings. The body of evidence includes high-quality Randomized Controlled Trials (RCTs) and systematic reviews. These studies were applied in research exploring how symptoms change over time for adults with symptomatic CVI, ranging from initial symptoms like discomfort and heaviness to more advanced manifestations.

The research examined outcomes related to physical discomfort, monitoring patient-reported outcomes describing perceived discomfort such as the severity of leg pain and night cramping. Studies also monitored objective clinical measures, including changes in leg circumference, a measure used in studies to monitor venous edema (swelling). Findings describe patterns observed in the studies where changes in these specific measured outcomes were reported in the short-term observation periods. In advanced cases, studies explored outcomes related to the healing rate of venous ulcers, with findings that contribute to understanding complication resolution patterns. Measured outcomes reflecting daily functioning or activity level showed variability across the studies that reported symptom change.

Evidence for Hemorrhoidal Disease Management

The active ingredient was also evaluated in studies focusing on Hemorrhoidal Disease, particularly conditions involving periods of heightened symptoms or acute episodes. The research used RCTs to explore short-term symptom changes, focusing on outcomes describing episodic or acute changes experienced during flare-ups. Studies monitored patient-reported outcomes describing perceived discomfort, specifically changes in anal pain, bleeding events, and swelling. Findings that focused on recording the timing and degree of change in pain scores and bleeding events during acute episodes are available from trials.

Research Gaps and Areas of Uncertainty

The research provides context, but evidence highlights what is known and what is still uncertain about the ingredient's role. One key limitation is that evidence quality varies across studies, and some systematic reviews have noted subgroup findings are uncertain due to the size or design of the original trials. Another limitation is that studies focusing on episodes where symptoms become more noticeable often have follow-up durations that were limited, making it challenging to draw conclusions about the long-term course of the condition. Furthermore, findings were mixed when trying to establish consistent changes in Quality of Life scores across all trials. Long-term effects are not fully established; data are still emerging for very older adults and pregnant populations.

Key Studies & References

Label: VASCULERA- diosmiplex tablet - DailyMed (Official Prescription Medical Food Information)

Frequently Asked Questions (FAQ)

Common questions about Vasculera (FAQ)

Q: Is Vasculera intended for permanent use, or is it a short-term treatment?

The use of Vasculera depends on the condition being managed. For the maintenance of Chronic Venous Disease (CVD), the official prescribing regimen is intended for sustained, daily maintenance intake. However, for acute episodes like hemorrhoidal flares, a short-term regimen is outlined in the regulatory documentation.

Q: What is Diosmiplex, and is it a natural or synthetic ingredient?

Diosmiplex is the active ingredient, classified as a high-density micronized flavonoid blend. Official information describes it as being semi-synthetically derived from natural bioflavonoids that originate in citrus fruits. The micronization process is a technical refinement that modifies the compound's properties.

Q: How long does it usually take for patients to notice a benefit from Vasculera?

The time it takes to see a benefit can vary depending on the condition. Studies on symptoms such as varicose veins, spider veins, or fluid accumulation (edema) show results may not be observed for 4 to 8 weeks. For more advanced issues, such as venous ulcers, the regulatory documents indicate that results may not be seen for several months.

Q: Does Vasculera interact with common over-the-counter pain medications like ibuprofen or acetaminophen?

Official regulatory information describes that the active ingredient can inhibit certain metabolic enzyme pathways in the body. This means caution is advised when taking it with other medicines that use these same pathways, such as Diclofenac. It is important to discuss all co-administered products with a healthcare provider.

Q: Does Vasculera interact with common vitamins or herbal supplements?

Regulatory guidance recommends patients inform their physician about all products they are currently using. This includes all prescribed medications, over-the-counter drugs, and any vitamin or herbal supplements. This information assists the doctor in supervising its use.

Q: Is there a maximum age limit for safely using this product?

Vasculera is indicated for use in adults. Although research studies have been conducted across a range of adult ages, regulatory summaries note that specific data is still emerging for very older adults.

Q: Does Vasculera help with the appearance of spider veins as well as varicose veins?

Vasculera is indicated for the clinical dietary management of Chronic Venous Disease (CVD). Official documentation states that CVD includes manifestations such as both varicose veins and spider veins.

Q: Does Vasculera contain gluten, lactose, or other common allergens?

According to the official product information, the tablets do not contain common components such as lactose or gluten. However, the product is strictly contraindicated for individuals who have a known hypersensitivity or allergy to corn products.

Q: Does Vasculera work by thinning the blood?

No, the primary mechanisms of action are focused on increasing the tone of the veins and helping to manage the integrity of the microcirculation. The official regulatory description of the drug's activity does not include a function related to thinning the blood or anti-coagulation.

Q: Are there any long-term safety concerns associated with taking Vasculera for many years?

The active component has an established history of use in Europe, where it has been available as a prescription product for over 30 years. Clinical studies have examined its safety profile. However, official regulatory text also notes that some trials had limited follow-up periods.

Q: Can Vasculera be taken at the same time as blood pressure medication?

Official documentation has observed that small decreases in both systolic and diastolic blood pressure have been noted in some studies. This information indicates why use alongside blood pressure medications requires the supervision of a healthcare provider.

Q: Can people with diabetes safely use Vasculera?

Clinical studies have specifically noted that the components of this product have not shown effects on blood glucose levels, insulin levels, or insulin resistance. As with any pre-existing medical condition, use is at the discretion and under the supervision of the physician.

Q: Is Vasculera suitable for use by patients who have high blood pressure?

Some studies have noted small decreases in both systolic and diastolic blood pressure. For patients with high blood pressure, use is at the discretion and under the supervision of a physician.

Q: Can patients with a history of cancer use Vasculera?

Official prescribing information advises against the use of this product in individuals who have a history of cancer. This restriction is in place because specific clinical studies have not been conducted in this patient population.

Q: Does Vasculera cause weight gain or weight loss?

Weight gain or weight loss is not listed among the commonly, uncommonly, or rarely documented adverse reactions in the official safety profile. Side effects are primarily centered on the gastrointestinal and nervous system domains.

Q: Has the main ingredient in Vasculera been used in other countries for many years?

Yes, the active ingredient, diosmin, has an established history of use internationally. Regulatory-aligned information indicates it has been used as a prescription product in Europe for over 30 years for the treatment of chronic venous insufficiency and its complications.

Q: Where can I find reliable, independent information about Vasculera's clinical studies?

Information regarding clinical trial data and registry details for products containing the active ingredients is available through government resources. These resources include government registries such as ClinicalTrials.gov.

Q: Does Vasculera affect cholesterol or blood sugar levels?

Official clinical studies have noted no effects of the product’s components on blood glucose, insulin levels, or insulin resistance. The safety profile does not address or list any documented effects related to cholesterol levels.

How should Vasculera be stored and disposed of?

How to Store and Dispose of Vasculera

Vasculera tablets must be stored according to official regulatory requirements to maintain product stability. All storage and disposal information is based on governmental labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature (between 59 F and 86 F, or 15 C and 30 C).
Protection	The product must be protected from light, moisture, and excessive heat.
Container	Store in the original container.
Child Safety	Keep out of the sight and reach of children and pets.

Disposal Requirements

Unused or expired Vasculera should be disposed of properly. The preferred method is using a drug take-back program (e.g., mail-back envelopes or authorized drop-off locations). If a take-back option is unavailable, the product should be mixed with an undesirable substance (like coffee grounds or dirt) in a sealed bag before being placed in the household trash. It must not be flushed down the toilet.

Vasculera